- Home
- PIM vs FBRX Comparison
PIM vs FBRX Comparison
Compare PIM & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIM
- FBRX
- Stock Information
- Founded
- PIM 1988
- FBRX N/A
- Country
- PIM United States
- FBRX United States
- Employees
- PIM N/A
- FBRX N/A
- Industry
- PIM Finance Companies
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- PIM Finance
- FBRX Health Care
- Exchange
- PIM Nasdaq
- FBRX Nasdaq
- Market Cap
- PIM 168.6M
- FBRX 154.5M
- IPO Year
- PIM N/A
- FBRX N/A
- Fundamental
- Price
- PIM $3.35
- FBRX $12.08
- Analyst Decision
- PIM
- FBRX Strong Buy
- Analyst Count
- PIM 0
- FBRX 3
- Target Price
- PIM N/A
- FBRX $68.00
- AVG Volume (30 Days)
- PIM 57.5K
- FBRX 87.9K
- Earning Date
- PIM 01-01-0001
- FBRX 11-13-2025
- Dividend Yield
- PIM 8.28%
- FBRX N/A
- EPS Growth
- PIM N/A
- FBRX N/A
- EPS
- PIM 0.05
- FBRX N/A
- Revenue
- PIM N/A
- FBRX N/A
- Revenue This Year
- PIM N/A
- FBRX N/A
- Revenue Next Year
- PIM N/A
- FBRX N/A
- P/E Ratio
- PIM $63.80
- FBRX N/A
- Revenue Growth
- PIM N/A
- FBRX N/A
- 52 Week Low
- PIM $2.90
- FBRX $4.11
- 52 Week High
- PIM $3.28
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- PIM 33.70
- FBRX 41.69
- Support Level
- PIM $3.35
- FBRX $13.76
- Resistance Level
- PIM $3.44
- FBRX $14.99
- Average True Range (ATR)
- PIM 0.04
- FBRX 1.22
- MACD
- PIM -0.01
- FBRX -0.41
- Stochastic Oscillator
- PIM 8.67
- FBRX 12.75
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).